Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ROIVNASDAQ:RVMDNASDAQ:VCELNASDAQ:VRNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeROIVRoivant Sciences$11.21-0.3%$10.59$8.73▼$13.06$8.00B1.235.53 million shs5.09 million shsRVMDRevolution Medicines$40.38-0.5%$37.73$29.17▼$62.40$7.52B1.111.52 million shs1.47 million shsVCELVericel$43.17+3.8%$41.28$37.39▼$63.00$2.17B1.31417,391 shs549,264 shsVRNAVerona Pharma$83.98-1.0%$66.82$11.79▼$86.86$6.81B0.21.31 million shs1.32 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceROIVRoivant Sciences-0.27%+5.56%-3.11%+5.75%+4.47%RVMDRevolution Medicines-0.49%+7.02%+1.48%+2.96%+1.51%VCELVericel+3.85%+2.54%+9.96%-11.46%-6.09%VRNAVerona Pharma-0.98%+13.59%+16.24%+27.88%+594.05%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationROIVRoivant Sciences2.3407 of 5 stars3.53.00.00.01.82.50.0RVMDRevolution Medicines4.1366 of 5 stars4.50.00.04.72.32.50.0VCELVericel3.2597 of 5 stars3.53.00.00.03.20.81.9VRNAVerona Pharma1.7028 of 5 stars2.61.00.00.03.12.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceROIVRoivant Sciences 3.00Buy$17.5056.11% UpsideRVMDRevolution Medicines 3.00Buy$67.0866.13% UpsideVCELVericel 3.00Buy$61.1441.63% UpsideVRNAVerona Pharma 3.11Buy$82.13-2.21% DownsideCurrent Analyst Ratings BreakdownLatest VCEL, ROIV, RVMD, and VRNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025VRNAVerona PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$85.00 ➝ $90.005/28/2025ROIVRoivant SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.005/22/2025VCELVericelStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$67.00 ➝ $67.005/14/2025RVMDRevolution MedicinesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$73.00 ➝ $72.005/8/2025RVMDRevolution MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$67.005/8/2025RVMDRevolution MedicinesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$70.00 ➝ $75.005/8/2025RVMDRevolution MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$87.00 ➝ $80.005/8/2025RVMDRevolution MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$57.00 ➝ $57.004/30/2025VRNAVerona PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$93.00 ➝ $107.004/30/2025VRNAVerona PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$75.00 ➝ $85.004/28/2025VRNAVerona PharmaCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookROIVRoivant Sciences$29.05M275.32N/AN/A$7.76 per share1.44RVMDRevolution Medicines$742K10,136.79N/AN/A$11.09 per share3.64VCELVericel$238.54M9.11$0.01 per share3,081.95$4.73 per share9.13VRNAVerona Pharma$118.54M57.44N/AN/A$3.10 per share27.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateROIVRoivant Sciences$4.35B-$0.25N/AN/AN/A-119.54%-14.05%-12.81%8/6/2025 (Estimated)RVMDRevolution Medicines-$436.37M-$4.00N/AN/AN/AN/A-33.67%-30.08%8/6/2025 (Estimated)VCELVericel-$3.18M$0.03719.6298.11N/A1.56%1.48%0.96%7/30/2025 (Estimated)VRNAVerona Pharma-$54.37M-$2.00N/A2,799.33N/AN/A-79.54%-43.49%8/14/2025 (Estimated)Latest VCEL, ROIV, RVMD, and VRNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2025Q4 2025ROIVRoivant Sciences-$0.16-$0.31-$0.15-$0.29$62.17 million$7.57 million5/8/2025Q1 2025VCELVericel-$0.09-$0.23-$0.14-$0.23$53.86 million$52.60 million5/7/2025Q1 2025RVMDRevolution Medicines-$1.12-$1.13-$0.01-$1.13N/AN/A4/29/2025Q1 2025VRNAVerona Pharma-$0.22$0.27+$0.49-$0.16$41.47 million$98.65 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthROIVRoivant SciencesN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/AVRNAVerona PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioROIVRoivant SciencesN/A37.9137.91RVMDRevolution MedicinesN/A14.2414.24VCELVericelN/A4.614.23VRNAVerona Pharma0.9313.0312.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipROIVRoivant Sciences64.76%RVMDRevolution Medicines94.34%VCELVericelN/AVRNAVerona Pharma85.88%Insider OwnershipCompanyInsider OwnershipROIVRoivant Sciences7.90%RVMDRevolution Medicines8.20%VCELVericel5.20%VRNAVerona Pharma4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableROIVRoivant Sciences860713.55 million657.18 millionOptionableRVMDRevolution Medicines250186.27 million154.76 millionOptionableVCELVericel30050.34 million46.79 millionOptionableVRNAVerona Pharma3081.08 million76.10 millionOptionableVCEL, ROIV, RVMD, and VRNA HeadlinesRecent News About These CompaniesRFG Advisory LLC Invests $1.48 Million in Verona Pharma plc (NASDAQ:VRNA)June 5 at 5:11 AM | marketbeat.comHennion & Walsh Asset Management Inc. Purchases 5,766 Shares of Verona Pharma plc (NASDAQ:VRNA)June 3 at 7:46 AM | marketbeat.comHamilton Lane Advisors LLC Takes $1.65 Million Position in Verona Pharma plc (NASDAQ:VRNA)June 3 at 6:44 AM | marketbeat.comHC Wainwright Forecasts Strong Price Appreciation for Verona Pharma (NASDAQ:VRNA) StockJune 3 at 2:09 AM | americanbankingnews.comVerona Pharma (NASDAQ:VRNA) Reaches New 12-Month High Following Analyst UpgradeJune 3 at 1:15 AM | americanbankingnews.comVerona Pharma (NASDAQ:VRNA) Hits New 1-Year High After Analyst UpgradeJune 2 at 10:35 AM | marketbeat.comVerona Pharma (NASDAQ:VRNA) Price Target Raised to $90.00 at HC WainwrightJune 2 at 8:17 AM | marketbeat.comTwo Sigma Advisers LP Buys New Shares in Verona Pharma plc (NASDAQ:VRNA)June 2 at 4:07 AM | marketbeat.com7,800 Shares in Verona Pharma plc (NASDAQ:VRNA) Acquired by Northern Trust CorpJune 2 at 3:14 AM | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Shares Sold by Bank of America Corp DEJune 1, 2025 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Shares Gap Up - What's Next?June 1, 2025 | americanbankingnews.comVerona Pharma plc (NASDAQ:VRNA) CFO Mark W. Hahn Sells 32,432 SharesMay 31, 2025 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) CEO Sells $320,208.00 in StockMay 31, 2025 | marketbeat.comDavid Zaccardelli Sells 157,704 Shares of Verona Pharma plc (NASDAQ:VRNA) StockMay 31, 2025 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) CFO Mark W. Hahn Sells 162,704 SharesMay 31, 2025 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) CFO Mark W. Hahn Sells 204,864 SharesMay 31, 2025 | marketbeat.comDavid Zaccardelli Sells 208,696 Shares of Verona Pharma plc (NASDAQ:VRNA) StockMay 31, 2025 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Shares Gap Up - Time to Buy?May 31, 2025 | marketbeat.com10,310 Shares in Verona Pharma plc (NASDAQ:VRNA) Bought by NorthCrest Asset Manangement LLCMay 31, 2025 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) CFO Sells $309,076.96 in StockMay 30, 2025 | insidertrades.comJim Cramer Notes Verona Pharma plc (VRNA) “Loses a Lot of Money”May 29, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVCEL, ROIV, RVMD, and VRNA Company DescriptionsRoivant Sciences NASDAQ:ROIV$11.21 -0.03 (-0.27%) As of 06/4/2025 04:00 PM EasternRoivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.Revolution Medicines NASDAQ:RVMD$40.38 -0.20 (-0.49%) As of 06/4/2025 04:00 PM EasternRevolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Vericel NASDAQ:VCEL$43.17 +1.60 (+3.85%) As of 06/4/2025 04:00 PM EasternVericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.Verona Pharma NASDAQ:VRNA$83.98 -0.83 (-0.98%) As of 06/4/2025 04:00 PM EasternVerona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Robinhood Stock Keeps Giving Investors Reasons To Buy CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast Guidewire Rockets Higher: A Move Above $300 Is Probable TSMC Joins NVIDIA in UAE Push, Fueling Growth Outlook Intuit's AI Boom: Stock Soaring, But Should Investors Hit Pause? Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge Analog Devices' Cyclical Recovery Story Has Just Begun Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
